Bortezomib inhibits human osteoclastogenesis

Area of Science:

• Molecular Biology
• Oncology
• Bone Biology

Background:

• Overexpression of RANKL in multiple myeloma drives osteoclast activation and bone resorption via NF-kappaB and AP-1 pathways.
• Understanding the role of proteasome and NF-kappaB signaling in osteoclastogenesis is crucial for therapeutic development.

Purpose of the Study:

• To investigate the effects of proteasome inhibition on RANKL-induced osteoclastogenesis.
• To compare proteasome inhibition with selective NF-kappaB inhibition using bortezomib and PS-1145.

Main Methods:

• Primary human osteoclasts were differentiated from CD14+ precursors with RANKL and M-CSF.
• Cells were treated with bortezomib (proteasome inhibitor) and PS-1145 (I-kappaB kinase inhibitor).
• Osteoclast differentiation, bone resorption, and signaling pathway activation (p38, AP-1, NF-kappaB) were assessed.

Main Results:

• Both bortezomib and PS-1145 dose- and time-dependently inhibited osteoclast differentiation and bone resorption.
• Early differentiation involved p38 MAPK pathway inhibition; later stages were affected by p38, AP-1, and NF-kappaB inhibition.
• AP-1 blockade significantly reduced osteoclast-derived VEGF production.

Conclusions:

• Proteasome inhibition effectively suppresses RANKL-induced osteoclastogenesis and bone resorption.
• This mechanism involves the inhibition of key signaling pathways including p38, AP-1, and NF-kappaB.
• Proteasome inhibition represents a promising therapeutic strategy for managing cancer-induced lytic bone disease.